Advancements in the Application of Proteogenomic in Assisting the Discovery of Novel Cancer Antigens

Di Zhao

doi:10.62051/7h3gkc06

Authors

Di Zhao

DOI:

https://doi.org/10.62051/7h3gkc06

Keywords:

Proteogenomic; Cancer; Cancer antigens; Immunotherapy.

Abstract

Over 18.1 million patients worldwide affected by more than 100 different types of cancer. Cancer is one of the critical focuses of medical research today. Researchers have discovered numerous types of cancer, with many patients and a lack of effective unified treatment methods. Therefore, it is urgent to study the pathogenesis and treatment methods. Proteogenomic is an interdisciplinary field focusing on genomics, transcriptomics, and proteomics, which has shown significant effectiveness in tumor analysis and treatment development. Its comprehensive analysis capabilities can help scientists and physicians accurately discover, predict, and treat cancer. This article summarizes the relevant content of using proteogenomic in analyzing and treating various cancers in recent years. It explores the role of proteogenomic in assisting the discovery of new antigens for cancer immunotherapy. This review highlights the latest advancements in proteogenomic and its significant findings in cancer analysis and treatment, suggesting a promising future for its integration into clinical practice.

Downloads

Download data is not yet available.

References

Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73 (1): 17 - 48.

Nesvizhskii AI. Proteogenomics: concepts, applications and computational strategies. Nat Methods, 2014, 11 (11): 1114 - 25.

Rodriguez H, Zenklusen JC, Staudt LM, et al. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell, 2021, 184 (7): 1661 - 1670.

Krug K, Jaehnig EJ, Satpathy S, et al. Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell, 2020, 183 (5):1436 - 1456.e31.

Anurag M, Jaehnig EJ, Krug K, et al. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov, 2022, 12 (11): 2586 - 2605.

Gillette MA, Satpathy S, Cao S, et al. Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell, 2020, 182 (1): 200 - 225.e35.

Soltis AR, Bateman NW, Liu J, et al. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways. Cell Rep Med, 2022, 3 (11): 100819.

Chen YJ, Roumeliotis TI, Chang YH, et al. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. Cell, 2020, 182 (1): 226 - 244.e17.

Vasaikar S, Huang C, Wang X, et al. Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. Cell, 2019, 177 (4): 1035 - 1049.e19.

Wang N, Wang R, Li X, et al. Tumor Microenvironment Profiles Reveal Distinct Therapy-Oriented Proteogenomic Characteristics in Colorectal Cancer. Front Bioeng Biotechnol, 2021, 9: 757378.

Sinha A, Huang V, Livingstone J, et al. The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell, 2019, 35 (3): 414 - 427.e6.

Charmpi K, Guo T, Zhong Q, et al. Convergent network effects along the axis of gene expression during prostate cancer progression. Genome Biol, 2020, 21 (1): 302.

Lima T, Barros AS, Trindade F, et al. Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study. Cancers (Basel), 2022, 14 (8): 2001.

Xu D, Zhu X, Ren J, et al. Quantitative proteomic analysis of cervical cancer based on TMT-labeled quantitative proteomics. J Proteomics, 2022, 252: 104453.